In Resectable Esophageal, EGJ Cancer, Chemoradiotherapy Improves Survival

Share this content:
Neoadjuvant chemoradiotherapy improves overall survival when added to surgery in esophageal or esophagogastric junctional cancer.
Neoadjuvant chemoradiotherapy improves overall survival when added to surgery in esophageal or esophagogastric junctional cancer.

Long-term follow-up confirms that neoadjuvant chemoradiotherapy improves overall survival when added to surgery in patients with resectable esophageal or esophagogastric junctional cancer, a new study published online ahead of print in the journal The Lancet Oncology has shown.

Initial results from the CROSS Study demonstrated improved 5-year overall survival with chemoradiotherapy plus surgery compared with surgery alone in patients with squamous cell carcinoma and adenocarcinoma of the esophagus or esophagogastric junction. Now, researchers report the long-term results after a minimum of 5 years follow-up.

For the study, researchers enrolled 368 patients with clinically resectable, locally advanced esophageal or esophagogastric junctional cancer. Participants were randomly assigned to receive neoadjuvant carboplatin and paclitaxel with concurrent radiotherapy followed by surgery, or surgery alone.

Results showed that after a median follow-up 84.1 months, median overall survival was 48.6 months and 24.0 months with neoadjuvant chemoradiotherapy plus surgery and surgery alone, respectively (HR = 0.68; 95% CI: 0.53, 0.88; P=0.003)

Among patients with squamous cell carcinoma, median overall survival was 81.6 months and 21.1 months, respectively (HR = 0.48; 95% CI: 0.28, 0.83;P=0.008), and 43.2 and 27.1 months, respectively for patients with adenocarcinoma (HR = 0.73; 95% CI: 0.55, 0.98; P=0.038).

RELATED: Salvage Surgery in the Management of Esophageal Cancer

The findings suggest that neoadjuvant chemoradiotherapy followed by surgical resection should be the standard of care for patients with resectable locally advanced adenocarcinoma or squamous cell carcinoma of the esophagus or esophagogastric junction.

Reference

  1. Shapiro J, van Lanschot JJB, Holshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junction cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015. [epub ahead of print]. doi: 10.1016/S1470-2045(15)00040-6.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters